Nonetheless, HER2-low BC is considered altogether with those with 0+ at IHC as HER2-negative, for the purpose of current treatment decisions (i.e., non-eligible for anti-HER2 therapies) [14,15,16]. This evidence concerns the gene ERBB2 and breast cancer.